Amunix Pharmaceuticals Inc

Standard BioTools Inc is a leading biotechnology company based in South San Francisco, CA, specializing in the development and distribution of cutting-edge instruments, kits, and services for genomics, cytometry, and imaging mass cytometry. Their comprehensive range of products includes the CyTOF XT and Helios systems, the Hyperion Imaging System, and the Biomark X9 System, among others, catering to various research areas such as biomarker discovery, immune profiling, infectious diseases, and single-cell analysis. With a strong focus on innovation and scientific excellence, Standard BioTools Inc offers a wide array of resources, including customer stories, videos, and scientific consultation, to support researchers in their translational and clinical research endeavors. Their commitment to providing high-quality products and customized services has established them as a trusted partner in the biotechnology industry.Generated from the website

Sana Biotechnology is a leading biotechnology company based in South San Francisco, CA, dedicated to revolutionizing medicine through the development of engineered cells as innovative treatments for various diseases. With a deep understanding of the genetic and cellular underpinnings of diseases, Sana aims to deliver accessible and impactful medicines that can significantly improve patient outcomes. Comprised of a team of exceptional individuals with expertise in cellular biology, machine learning, and therapeutic development, Sana Biotechnology is committed to making groundbreaking discoveries that will change the lives of patients and their families. Their pipeline of innovative drug candidates holds the potential to disrupt the treatment landscape across a diverse range of diseases, with the ultimate goal of delivering cures that strike at the heart of disease.Generated from the website

Pionyr Immunotherapeutics, Inc., a biotechnology company based in South San Francisco, CA, was acquired by Ikena Oncology, Inc. in August 2023. Their innovative Myeloid Tuning programs aim to enhance the immune system's anti-tumor response by modifying the cellular infiltrate of the tumor microenvironment. With clinical programs targeting TREM2 and TREM1, Pionyr focuses on selectively depleting and reprogramming tumor-associated macrophages responsible for immunosuppression, demonstrating safety in Phase 1a b trials alone and in combination with pembrolizumab. Additionally, their IND-ready program, PY265 anti-MARCO, aims to activate the immune system in the tumor microenvironment. Pionyr Immunotherapeutics has made significant contributions to the field of immunotherapy, as evidenced by their posters, publications, and whitepapers. As part of Ikena Oncology, the company's business development team is open to discussions regarding licensing and partnerships for their pioneering programs. With a commitment to advancing cancer treatment, Pionyr Immunotherapeutics continues to make strides in developing novel therapies to combat tumors and improve patient outcomes.Generated from the website